ESMO Congress

Iza-bren shows significant improvement in response rates for recurrent nasopharyngeal carcinoma compared to chemotherapy, offering new hope for patients.

Zipalertinib shows promising efficacy in treating non-small cell lung cancer with CNS metastases, highlighting its potential as a new therapeutic option.

Tislelizumab enhances treatment outcomes in esophageal squamous cell carcinoma, showing improved response rates and survival compared to standard chemoradiotherapy.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Sirexatamab combined with bevacizumab shows promise in improving survival for DKK1-high metastatic colorectal cancer patients, according to recent trial results.

The DREAM3R trial explores durvalumab plus chemotherapy for advanced pleural mesothelioma, revealing promising survival rates despite early study limitations.

Adjuvant therapy shows promise in achieving ctDNA clearance in colorectal cancer patients, correlating with improved disease-free survival outcomes.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

Sacituzumab govitecan significantly improves progression-free survival in advanced triple-negative breast cancer, offering a promising alternative to chemotherapy.

The ALPHAMEDIX-02 trial showed promising results for 212Pb-DOTAMTATE in previously treated gastroenteropancreatic neuroendocrine tumors.

New trial results reveal capivasertib enhances survival in advanced prostate cancer, offering hope for patients with PTEN deficiency.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

Gedatolisib enhances progression-free survival in advanced breast cancer patients, showcasing significant benefits when combined with fulvestrant and palbociclib.

New trial data reveals T-DXd plus THP significantly improves pathologic complete response rates in high-risk HER2-positive early breast cancer patients.

Sacituzumab tirumotecan significantly improves progression-free survival in HR+/HER2– breast cancer compared with traditional chemotherapy.

The SKYSCRAPER-03 trial showed that consolidation tiragolumab plus atezolizumab does not improve progression-free survival in advanced lung cancer compared to durvalumab.

Cemiplimab shows comparable second primary tumor rates to placebo while improving disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

New trial data reveals T-DXd significantly improves disease-free survival in high-risk HER2-positive breast cancer patients compared to T-DM1, offering hope for better outcomes.

New findings from the CheckMate 238 trial highlight nivolumab's superior long-term efficacy over ipilimumab in treating advanced melanoma.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

BNT111 combined with cemiplimab shows promising efficacy in treating PD-(L)1-relapsed melanoma, achieving significant response rates and manageable safety profiles.

The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.

Tarlatamab combined with frontline chemoimmunotherapy shows promising safety and efficacy in extensive-stage small cell lung cancer patients.

XTR008 therapy shows significant benefits in treating GEP-NETs, enhancing survival rates and quality of life compared to octreotide LAR.

Giredestrant combined with everolimus significantly enhances progression-free survival in advanced ER-positive breast cancer, offering a promising new treatment option.

Pimicotinib shows promising long-term efficacy in treating tenosynovial giant cell tumor, achieving high response rates and durable outcomes in patients.

Combination therapy of osimertinib and chemotherapy significantly enhances overall survival in patients with EGFR-mutated advanced lung cancer, surpassing monotherapy outcomes.

Combining local consolidative therapy with osimertinib enhances progression-free survival in metastatic EGFR-mutant non-small cell lung cancer patients.